Nikhil Munshi, MD

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma PURPOSEThe diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early ...

Very important new paper by Samur et al on SMM in JCO - will change our thinking! @pedalheadphx.bsky.social @myeloma-society.bsky.social @themmrf.bsky.social @imfmyeloma.bsky.social @szusmani.bsky.social

# ascopubs.org/doi/10.1200/...

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social

#ASH24 myeloma, gene expression review of genes in 17p del patients only PKMYT1 is over expressed and KO is lethal, drug exist that seems to be uniquely effective. High potential for benefit observation from @nikhilmunshi.bsky.social lab

Development of hyperdiploidy starts at an early age and takes a decade to complete Key Points. First hyperdiploidy event occured within the first three decades of life and took a decade to completeA MM cell accumulated on median 0.56 muta

doi.org/10.1182/bloo...

An interesting paper in Blood by Dr. Samur suggesting that the cell that eventually becomes myeloma first acquires extra chromosome in 2nd decade of life and becomes fully hyperdiploid by 3rd. Implication for many cancers. @pedalheadphx.bsky.social @auclairdan.bsky.social @szusmani.bsky.social

Welcoming all myeloma colleagues and science and medicine interested to this platform and group ! @myeloma-society.bsky.social; @imfmyeloma.bsky.social;